Price Action Alert: What Next for Revance Therapeutics Inc Stock After Today’s Huge Decline?

Price Action Alert: What Next for Revance Therapeutics Inc Stock After Today's Huge Decline?

The stock of Revance Therapeutics Inc (NASDAQ:RVNC) is a huge mover today! The stock decreased 5.71% or $0.8 during the last trading session, hitting $13.2. About 238,913 shares traded hands or 45.36% up from the average. Revance Therapeutics Inc (NASDAQ:RVNC) has declined 30.73% since April 6, 2016 and is downtrending. It has underperformed by 32.68% the S&P500.
The move comes after 8 months negative chart setup for the $390.34M company. It was reported on Nov, 8 by Barchart.com. We have $11.48 PT which if reached, will make NASDAQ:RVNC worth $50.74 million less.

Analysts await Revance Therapeutics Inc (NASDAQ:RVNC) to report earnings on November, 14. They expect $-0.90 earnings per share, down 11.11% or $0.09 from last year’s $-0.81 per share. After $-0.88 actual earnings per share reported by Revance Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.27% negative EPS growth.

Revance Therapeutics Inc (NASDAQ:RVNC) Ratings Coverage

Out of 4 analysts covering Revance Therapeutics (NASDAQ:RVNC), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Revance Therapeutics has been the topic of 5 analyst reports since August 22, 2015 according to StockzIntelligence Inc. The rating was maintained by Suntrust Robinson on Tuesday, June 14 with “Buy”. The stock of Revance Therapeutics Inc (NASDAQ:RVNC) earned “Buy” rating by Guggenheim on Monday, November 23. SunTrust initiated Revance Therapeutics Inc (NASDAQ:RVNC) rating on Wednesday, March 23. SunTrust has “Buy” rating and $46 price target. The company was downgraded on Saturday, August 22 by Zacks. The company was downgraded on Tuesday, June 14 by Brean Capital.

According to Zacks Investment Research, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.”

Insitutional Activity: The institutional sentiment increased to 1.39 in 2016 Q2. Its up 0.32, from 1.07 in 2016Q1. The ratio increased, as 15 funds sold all Revance Therapeutics Inc shares owned while 16 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 28.60 million shares or 5.50% more from 27.11 million shares in 2016Q1.
Nottingham Advsr last reported 16,312 shares in the company. Wellington Group Ltd Liability Partnership holds 0.01% or 2.34 million shares in its portfolio. Parametric Portfolio Assoc accumulated 21,068 shares or 0% of the stock. The New Jersey-based Blackrock Invest Ltd Com has invested 0% in Revance Therapeutics Inc (NASDAQ:RVNC). Royal State Bank Of Canada accumulated 0% or 19,228 shares. Metropolitan Life Insur Ny owns 13,299 shares or 0% of their US portfolio. Manufacturers Life Ins The holds 14,920 shares or 0% of its portfolio. Alliancebernstein L P holds 35,300 shares or 0% of its portfolio. Tekla Limited Liability holds 0.04% or 75,000 shares in its portfolio. Essex Investment Limited Liability Corp accumulated 81,701 shares or 0.18% of the stock. Alps Advsr has invested 0% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC). Jpmorgan Chase & Company, a New York-based fund reported 3.33 million shares. Lombard Odier Asset Management (Usa) Corp accumulated 0.04% or 22,515 shares. Polar Llp has 1.17 million shares for 0.3% of their US portfolio. Moreover, Federated Investors Pa has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 20,000 shares.

Insider Transactions: Since May 9, 2016, the stock had 0 buys, and 2 selling transactions for $196,449 net activity. Another trade for 12,000 shares valued at $178,199 was sold by Browne L Daniel. 1,000 shares were sold by Ruegg Curtis, worth $16,180 on Monday, May 9.

Another recent and important Revance Therapeutics Inc (NASDAQ:RVNC) news was published by Fool.com which published an article titled: “Why Revance Therapeutics Is Crashing 23% Today” on June 14, 2016.

RVNC Company Profile

Revance Therapeutics, Inc., incorporated on August 10, 1999, is a biotechnology company. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. The Company’s TransMTS technology enables delivery of botulinum toxin type A through approximately two investigational drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. The Company’s botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. First, its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Second, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment